Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. Personalized prescription of ACEI/ARBs for hypertensive COVID-19 patients

Personalized prescription of ACEI/ARBs for hypertensive COVID-19 patients

Thumbnail Image
Download
Name

10729_2021_9545_ReferencePDF.pdf

Size

638.08 KB

Format

Adobe PDF

Checksum (MD5)

4ae06eacc53e231f69dca6f2e5aedcb3

Download all files submitted through automated deposit
art_4821610735855141665.zip (498.03 KB)
Author(s)
Bertsimas, Dimitris
•
Borenstein, Alison
•
Mingardi, Luca
•
Nohadani, Omid
•
Orfanoudaki, Agni
•
Stellato, Bartolomeo
•
Wiberg, Holly
•
Sarin, Pankaj
•
Varelmann, Dirk J.
•
Estrada, Vicente
more
Date Issued
March 15, 2021
Publisher
Springer US
Version
Author's final manuscript
Abstract
Abstract The COVID-19 pandemic has prompted an international effort to develop and repurpose medications and procedures to effectively combat the disease. Several groups have focused on the potential treatment utility of angiotensin-converting–enzyme inhibitors (ACEIs) and angiotensin-receptor blockers (ARBs) for hypertensive COVID-19 patients, with inconclusive evidence thus far. We couple electronic medical record (EMR) and registry data of 3,643 patients from Spain, Italy, Germany, Ecuador, and the US with a machine learning framework to personalize the prescription of ACEIs and ARBs to hypertensive COVID-19 patients. Our approach leverages clinical and demographic information to identify hospitalized individuals whose probability of mortality or morbidity can decrease by prescribing this class of drugs. In particular, the algorithm proposes increasing ACEI/ARBs prescriptions for patients with cardiovascular disease and decreasing prescriptions for those with low oxygen saturation at admission. We show that personalized recommendations can improve patient outcomes by 1.0% compared to the standard of care when applied to external populations. We develop an interactive interface for our algorithm, providing physicians with an actionable tool to easily assess treatment alternatives and inform clinical decisions. This work offers the first personalized recommendation system to accurately evaluate the efficacy and risks of prescribing ACEIs and ARBs to hypertensive COVID-19 patients.
MIT Department
Sloan School of Management
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
http://creativecommons.org/licenses/by-nc-sa/4.0/
Persistent DSpace Link
https://hdl.handle.net/1721.1/136841
DOI of Published Version
https://doi.org/10.1007/s10729-021-09545-5
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.